Previously, the authors have identified that c-Met mediates reactivation of the PI3K/AKT pathway following BRAF inhibitor treatment in BRAF (V600E) mutant anaplastic thyroid cancer, thereby contributing to the acquired drug resistance. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.